Antares Pharma, Inc.
If you purchased Antares Pharma, Inc. securities and would like to join the action, please click "Join This Action" below.
ATRS STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF ANTARES PHARMA, INC. IS FAIR TO SHAREHOLDERS
April 13, 2022.
New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Antares Pharma, Inc. (NASDAQ: ATRS) to Halozyme Therapeutics, Inc. for $5.60 per share in cash is fair to Antares Pharma shareholders.
The investigation concerns whether Antares Pharma and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Antares Pharma shareholders; (2) determine whether Halozyme is underpaying for Antares Pharma; and (3) disclose all material information necessary for Antares Pharma shareholders to adequately assess and value the merger consideration. On behalf of Antares Pharma shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.